Working… Menu

Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism (Longheva)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01164046
Recruitment Status : Terminated (Due to slow inclusion of patients)
First Posted : July 16, 2010
Last Update Posted : December 3, 2014
Information provided by (Responsible Party):
Pieter W. Kamphuisen, MD PhD, University Medical Center Groningen

Brief Summary:


Patients with cancer and a first deep venous thrombosis of the leg or pulmonary embolism (venous thromboembolism, VTE) are generally treated with low molecular weight heparin (LMWH)injections for 6 months, since this treatment is associated with a reduced incidence of recurrent VTE compared to vitamin K antagonists (VKA). It is recommended that patients with active malignancy (metastatic cancer and/or ongoing cancer treatment)continue anticoagulant treatment. However, it is unknown whether LMWH is still superior compared to VKA for the long-term anticoagulant treatment.


The aim of this study is to evaluate whether low-molecular-weight heparin more effectively reduces recurrent VTE compared to vitamin K antagonists in patients with cancer who have already completed 6 to 12 months of anticoagulant treatment because of deep venous thrombosis of the leg or pulmonary embolism.


The investigators hypothesize that LMWH is more effective compared to VKA in the long-term treatment of VTE in cancer patients who have already been treated for 6-12 months with anticoagulants.


This is a multicenter, multinational, randomized, open label trial.


Patients with a malignancy (all types, solid and hematological) who have received 6-12 months of anticoagulation for VTE and have an indication for continuing anticoagulation, will be randomly assigned to six additional months of LMWH or VKA. LMWH will be administered in a weight-adjusted scheme, with 65-75% of therapeutic doses. All types of LMWH and VKA are allowed, as long as weight adjusted dosing is possible for LMWH. The target INR will be 2.0-3.0. The primary efficacy outcome is symptomatic recurrent VTE, i.e. deep vein thrombosis and pulmonary embolism. The primary safety outcome is major bleeding.

Sample size

A total of 65 to 87 recurrent VTE events are needed to show a 50% reduction with LMWH as compared to VKA (type I error 0.05, two-sided, power respectively 80 and 90%). To observe 75 events, with a 10% event rate per half year in the VKA arm and 5% in the LMWH arm a total of 1000 patients will need to be included.


Outcomes will be adjudicated by a central adjudication committee. A steering committee will be formed, preferably consisting of one member of every participating center. An electronic case report form will be used for data collection. Also, an electronic trial master file will be used.

Condition or disease Intervention/treatment Phase
Venous Thromboembolism Neoplasms Drug: low molecular weight heparin Drug: vitamin K antagonists Phase 3

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
Study Start Date : August 2010
Actual Primary Completion Date : July 2014
Actual Study Completion Date : July 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: vitamin K antagonists Drug: vitamin K antagonists
Target INR between 2-3. Any type allowed, if approved for use in that country.
Other Names:
  • phenprocoumon
  • acenocoumarol
  • warfarin

Active Comparator: Low molecular weight heparin Drug: low molecular weight heparin
weight adjusted dose of low molecular weight heparin, any type allowed if approved, 65-75% of full therapeutic dose
Other Names:
  • nadroparin
  • enoxaparin
  • tinzaparin
  • bemiparin
  • reviparin
  • dalteparin
  • certoparin

Primary Outcome Measures :
  1. Symptomatic recurrent VTE, i.e. the composite of recurrent deep venous thrombosis and fatal or non-fatal pulmonary embolism [ Time Frame: 6 months ]
    Primary efficacy outcome

Secondary Outcome Measures :
  1. All clinically relevant bleeding (i.e. major bleeding and other clinically relevant non-major bleeding) [ Time Frame: 6 months ]
    safety outcome

  2. all-cause mortality [ Time Frame: 6 months ]
    safety outcome

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with cancer and confirmed pulmonary embolism (PE) or deep vein thrombosis (DVT) of the leg who have been treated for minimally 6 and maximally 12 months with therapeutic doses of anticoagulants, i.e. LMWH or VKA or a new anticoagulant in a trial
  2. Written informed consent
  3. Indication for long-term anticoagulant therapy (e.g. because of metastasized disease, chemotherapy)

Exclusion Criteria:

  1. Legal age limitations (country specific), minimum age at least 18 years
  2. Indications for anticoagulant therapy other than DVT or PE
  3. Any contraindication listed in the local labeling of LMWH or VKA
  4. Childbearing potential without proper contraceptive measures, pregnancy or breastfeeding
  5. Life expectancy <3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01164046

Layout table for location information
United States, District of Columbia
George Washington University
Washington, District of Columbia, United States, 20037
Canada, Ontario
University Health Network
Toronto, Ontario, Canada
Medical Clinic Dresden University
Dresden, Germany
Ospedali Riuniti
Bergamo, Italy
Hospital d'Annunziata
Chieti, Italy
Ospedaliera di Padova
Padova, Italy
Arcispedale Santa Maria Nuova (ASMN)
Reggio Emilia, Italy
Ospedale di Circolo
Varese, Italy
Almere, Netherlands
Academic Medical Centre (AMC)
Amsterdam, Netherlands
Slotervaart Hospital
Amsterdam, Netherlands
Reinier de Graaf Groep
Delft, Netherlands
Medisch Spectrum Twente
Enschede, Netherlands
University Medical Centre Groningen (UMCG)
Groningen, Netherlands
Sponsors and Collaborators
University Medical Center Groningen
Layout table for investigator information
Principal Investigator: Pieter W. Kamphuisen, MD, PhD University Medical Center Groningen
Principal Investigator: Harry R. Buller, MD, PhD Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Study Chair: Steering Board Committee Representatives from participating centers


Layout table for additonal information
Responsible Party: Pieter W. Kamphuisen, MD PhD, Prof, University Medical Center Groningen Identifier: NCT01164046     History of Changes
Other Study ID Numbers: EudraCT nr: 2009-015336-15
Protocol nr: 29462 ( Other Identifier: CCMO The Netherlands )
First Posted: July 16, 2010    Key Record Dates
Last Update Posted: December 3, 2014
Last Verified: December 2014
Keywords provided by Pieter W. Kamphuisen, MD PhD, University Medical Center Groningen:
Heparin, Low-Molecular-Weight
recurrent venous thrombosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Vitamin K
Pulmonary Embolism
Venous Thromboembolism
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Calcium heparin
Heparin, Low-Molecular-Weight
Growth Substances
Physiological Effects of Drugs
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Antifibrinolytic Agents